Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model

Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model

<p><strong>Background</strong> The first gene therapy for an inherited retinal dystrophy recently received market approval in the United States; multiple other gene therapies are in the clinical pipeline. Thus far, gene therapy has commanded prices in the range of USD 500,000 to ov...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Halioua-Haubold, C-L, Jolly, JK, Smith, JA, Villanueva, R, Brindley, DA, MacLaren, RE
Natura:	Journal article
Pubblicazione:	Springer Nature 2019

Documenti analoghi

A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on quality adjusted life years (QALYs)
di: Halioua-Haubold, C, et al.
Pubblicazione: (2018)

Recent advances and future prospects in choroideremia
di: Zinkernagel MS, et al.
Pubblicazione: (2015-11-01)

Low luminance visual acuity and low luminance deficit in choroideremia and RPGR-associated retinitis pigmentosa
di: Wood, LJ, et al.
Pubblicazione: (2021)

Functional defects in color vision in patients with choroideremia
di: Jolly, J, et al.
Pubblicazione: (2015)

Longitudinal study to assess the quantitative use of fundus autofluorescence for monitoring disease progression in choroideremia
di: Dubis, AM, et al.
Pubblicazione: (2021)

Structural and functional characteristics of color vision changes in choroideremia
di: Jolly, JK, et al.
Pubblicazione: (2021)

The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype
di: Simunovic, M, et al.
Pubblicazione: (2016)

Characterizing the natural history of visual function in choroideremia using microperimetry and multimodal retinal imaging
di: Jolly, J, et al.
Pubblicazione: (2017)

Macular hole surgery in patients with end-stage choroideremia
di: Zinkernagel, MS, et al.
Pubblicazione: (2013)

Retinal degeneration in choroideremia follows an exponential decay function
di: Aylward, J, et al.
Pubblicazione: (2018)

Choroideremia: molecular mechanisms and development of AAV gene therapy
di: Patrício, M, et al.
Pubblicazione: (2018)

Structural and Functional Characteristics of Color Vision Changes in Choroideremia
di: Jasleen K. Jolly, et al.
Pubblicazione: (2021-10-01)

Colour discrimination ellipses in choroideremia
di: Seitz, IP, et al.
Pubblicazione: (2018)

Prenylation of rab6a as a potency assay for choroideremia gene therapy
di: Patricio, M, et al.
Pubblicazione: (2017)

Novel non-contiguous exon duplication in choroideremia
di: Edwards, T, et al.
Pubblicazione: (2017)

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
di: Han, RC, et al.
Pubblicazione: (2021)

Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial
di: MacLaren, RE, et al.
Pubblicazione: (2023)

Visual acuity after retinal gene therapy for Choroideremia
di: Edwards, T, et al.
Pubblicazione: (2016)

Regulatory considerations for gene therapy products in the US, EU, and Japan
di: Halioua-Haubold, C, et al.
Pubblicazione: (2017)

A detailed in vivo analysis of the retinal nerve fibre layer in choroideremia
di: Fu, D, et al.
Pubblicazione: (2018)

A qualitative and quantitative assessment of fundus autofluorescence patterns in patients with choroideremia
di: Jolly, J, et al.
Pubblicazione: (2016)

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
di: Xue, K, et al.
Pubblicazione: (2018)

The biological activity of AAV vectors for choroideremia gene therapy can be measured by in vitro prenylation of RAB6A
di: Patrício, M, et al.
Pubblicazione: (2018)

Microperimetry as an outcome measure in RPGR-associated retinitis pigmentosa clinical trials
di: Taylor, LJ, et al.
Pubblicazione: (2023)

Correlation of optical coherence tomography and autofluorescence in the outer retina and choroid of patients with choroideremia
di: Xue, K, et al.
Pubblicazione: (2016)

Retinal gene therapy in patients with choroideremia: Initial fi ndings from a phase 1/2 clinical trial
di: MacLaren, R, et al.
Pubblicazione: (2014)

Low‐contrast visual acuity versus low‐luminance visual acuity in choroideremia
di: Wood, L, et al.
Pubblicazione: (2020)

Macular hole surgery in patients with end-stage choroideremia.
di: Zinkernagel, MS, et al.
Pubblicazione: (2013)

Ocular gene therapy for choroideremia: clinical trials and future perspectives
di: Xue, K, et al.
Pubblicazione: (2018)

The Biological Activity of AAV Vectors for Choroideremia Gene Therapy Can Be Measured by In Vitro Prenylation of RAB6A
di: Maria I. Patrício, et al.
Pubblicazione: (2018-06-01)

Clinical Research on the Leading Causes of Severe Sight Impairment in the UK General and Working Populations
di: Liu WJ, et al.
Pubblicazione: (2023-09-01)

Digital technology in somatic and gene therapy trials of pediatric patients with ocular diseases: protocol for a scoping review
di: Meinert, E, et al.
Pubblicazione: (2019)

Low luminance visual acuity as a clinical measure and clinical trial outcome measure: a scoping review
di: Wood, LJ, et al.
Pubblicazione: (2021)

A cross-sectional study to assess the clinical utility of modern visual function assessments in patients with inherited retinal disease: a mixed methods observational study protocol
di: Taylor, LJ, et al.
Pubblicazione: (2023)

Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.
di: Barnard, A, et al.
Pubblicazione: (2014)

AAV2/2-CBA-REP1 Vector with WPRE Provides Functional Expression of the Transgene in Choroideremia Mouse Knock-Out and Patient Cells
di: Tolmachova, T, et al.
Pubblicazione: (2012)

Investigating the impact of asymmetric macular sensitivity on visual acuity chart reading in choroideraemia
di: Baffour‐Awuah, KA, et al.
Pubblicazione: (2024)

Genetic testing for choroideremia
di: Abeshi Andi, et al.
Pubblicazione: (2017-10-01)

Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo
di: Tolmachova, T, et al.
Pubblicazione: (2013)

Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial
di: Jasmina Cehajic-Kapetanovic, et al.
Pubblicazione: (2024-05-01)